PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

BackgroundChemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal for immunotherapy of cancer 2023-06, Vol.11 (6), p.e006833
Hauptverfasser:	Lo Russo, Giuseppe, Prelaj, Arsela, Dolezal, James, Beninato, Teresa, Agnelli, Luca, Triulzi, Tiziana, Fabbri, Alessandra, Lorenzini, Daniele, Ferrara, Roberto, Brambilla, Marta, Occhipinti, Mario, Mazzeo, Laura, Provenzano, Leonardo, Spagnoletti, Andrea, Viscardi, Giuseppe, Sgambelluri, Francesco, Brich, Silvia, Miskovic, Vanja, Pedrocchi, Alessandra Laura Giulia, Trovo', Francesco, Manglaviti, Sara, Giani, Claudia, Ambrosini, Paolo, Leporati, Rita, Franza, Andrea, McCulloch, John, Torelli, Tommaso, Anichini, Andrea, Mortarini, Roberta, Trinchieri, Giorgio, Pruneri, Giancarlo, Torri, Valter, De Braud, Filippo, Proto, Claudia, Ganzinelli, Monica, Garassino, Marina Chiara
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen - metabolism Biomarkers biomarkers, tumor Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy Clinical medicine Flow cytometry Gene expression Humans Immunotherapy Immunotherapy Biomarkers Ligands Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Monoclonal antibodies Multiomics non-small cell lung cancer Patients Prospective Studies Software Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BackgroundChemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1)
ISSN:	2051-1426 2051-1426
DOI:	10.1136/jitc-2023-006833